India Reinforces Its Position as the “Pharmacy of the World”; Targets US$ 50 Billion Pharma Exports by 2030

Hyderabad, 09 June 2026: Reaffirming its commitment to global health and healthcare accessibility, India has reiterated its vision of becoming a trusted partner in global health security under Prime Minister Shri Narendra Modi’s philosophy of “One Earth, One Health.”

India, widely recognized as the “Pharmacy of the World,” has earned global trust through its scale, quality, affordability, and dependable supply of medicines. Over the past 12 years, the Indian pharmaceutical industry has transformed into a strategic sector and a source of national pride, growing from approximately US$ 20 billion to US$ 60 billion, with projections to reach US$ 130 billion by 2030.

The country’s pharmaceutical exports have increased from US$ 14 billion in FY 2015 to US$ 31 billion in FY 2026, registering a CAGR of 7.22 percent. Today, India is the third-largest producer of pharmaceuticals by volume, supplying nearly 20 percent of the world’s generic medicines and exporting to more than 200 countries, with over 60 percent of exports destined for highly regulated markets.

The United States continues to be India’s largest pharmaceutical market, with exports valued at approximately US$ 10.5 billion, more than two-and-a-half times the 2014 level. India’s pharmaceutical footprint has also expanded significantly across Europe, Latin America, and Africa, with exports to France, Brazil, the United Kingdom, and South Africa witnessing robust growth over the last decade.

India’s strength lies in delivering quality, continuity, and affordability. The nation hosts over 1,000 US FDA-registered manufacturing sites, the highest number outside the United States, demonstrating its commitment to quality standards. Since 2023, India has supplied nearly 1,500 metric tonnes of medicines to 56 countries, reinforcing its role as a reliable healthcare partner during global disruptions.

Highlighting India’s contribution to global health, the statement noted that initiatives such as Vaccine Maitri during the COVID-19 pandemic showcased the country’s commitment to the principle of “Vasudhaiva Kutumbakam”—the world is one family—and strengthened India’s reputation as a dependable partner in times of crisis.

Looking ahead, India aims to transition from a volume-driven pharmaceutical industry to a value-driven innovation ecosystem. Future growth will be powered by biosimilars, biologics, gene therapies, specialty medicines, vaccines, complex generics, contract manufacturing, medical devices, and API self-reliance.

The Government’s recently launched Biopharma SHAKTI initiative, with an outlay of ₹10,000 crore over five years, is expected to boost biologics, biosimilars, clinical research infrastructure, and pharmaceutical innovation. Patent filings in the pharmaceutical sector have also more than doubled, reflecting India’s growing scientific and research capabilities.

India is additionally emerging as a global hub for pharmaceutical knowledge services. Global Capability Centres (GCCs) established by multinational pharmaceutical companies now employ over 30,000 professionals and have attracted investments exceeding US$ 300 million, supporting areas such as analytics, clinical operations, regulatory science, pharmacovigilance, digital health, and research.

The Government has set an ambitious target of achieving US$ 50 billion in pharmaceutical exports by 2030. To achieve this goal, India will continue to strengthen quality systems, build resilient supply chains for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), expand into high-value products, enhance contract manufacturing and clinical research capabilities, and leverage trade agreements to improve market access.

As global health security undergoes transformation, India stands ready with scale, skill, science, standards, and social commitment. The nation remains committed to its role as the “Pharmacy of the World,” while evolving into a hub for affordable innovation and a trusted partner in global healthcare.